ARG-007 has been shown to be safe and stable when given alongside a thrombolytic. Of course they would still give a thrombolytic for ischaemic stroke - what, you suggest leaving the blood clot there!?
If NYR ever trial our drug in ishaemic stroke, they will also need to show that it can be given with a thrombolytic.
I don't know how you could claim NYR has a more effective drug - clearly you have no grasp of science or statistics. We could only know when both complete clinical trials in the same indication.
I think the main reasons for NYRs low MC were the continued delays in reaching pre-clinical milestones, followed by the shock failure of their lead cholesterol-lowering candidate to pass toxicology studies. Makes sense that investors hae been wary since.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)